Shots: The EC’s approval is based on P-III MAIA study assessing Darzalex + lenalidomide and dexamethasone (DRd) vs Rd in 737 newly diagnosed patients aged 45-90yrs. with multiple myeloma ineligible […]readmore
Shots: The approval is based on P-III MAIA study assessing Darzalex + lenalidomide + dexamethasone (Rd) vs Rd as monothx. in 737 patients with newly diagnosed multiple myeloma who are […]readmore
Shots: The approval is based on P-III ALCYONE study results assessing Darzalex + VMP (bortezomib, melphalan and prednisone) vs VMP as monothx. in 706 newly diagnosed patients with multiple myeloma […]readmore
Copyright © 2020 Digiqole. All Right Reserved.